Emyria Limited (FRA:Q84)

Market Cap	20.61M -19.7%
Revenue (ttm)	2.45M +190.6%
Net Income	-3.70M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	221,000
Open	0.0270
Previous Close	0.0245
Day's Range	0.0270 - 0.0310
52-Week Range	0.0120 - 0.0640
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the Universi...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: Q84

Financial Performance

In fiscal year 2026, Emyria's revenue was 4.05 million, an increase of 190.62% compared to the previous year's 1.39 million. Losses were -6.11 million, 94.6% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 13, 2026

Data Sources Report a data error